Cholesterol Medicines
Methodology & AI Transparency ⓘ
Cholesterol Medicines Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is cholesterol? Cholesterol is a waxy, fat-like substance that's found in all the cells in your body.
- 2 Real-world patient consensus: Federal ICD-10-CM code E78.1 categorizes Cholesterol Medicines under Cholesterol, Triglycerides & Lipids.
- 3 Typical cash cost range: Clinicians assessing Cholesterol Medicines focus on impaired hepatic LDL-receptor in Cholesterol Medicines (E78.1: clearance) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Cholesterol Medicines: Apolipoprotein B (ApoB) [Cholesterol Medicines E78.1] (< 70 mg/dL (< 55 mg/dL high risk) (E78.1)) and LDL Cholesterol [Cholesterol Medicines E78.1].
Ask our AI Specialists anything about Cholesterol Medicines
What Is Cholesterol Medicines?
What is cholesterol? Cholesterol is a waxy, fat-like substance that's found in all the cells in your body. Your body needs some cholesterol to work properly. But if you have too much of it in your blood, it can stick to the walls of your arteries and narrow or even block them. This puts you at risk for coronary artery disease and other heart diseases . Cholesterol is made by your liver. It travels through the blood on proteins called lipoproteins. One type of lipoprotein, LDL , is sometimes called the "bad" cholesterol. A high LDL level leads to a buildup of cholesterol in your arteries. Another type, HDL , is sometimes called the "good" cholesterol.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Cholesterol Medicines (ICD-10 E78.1) is driven by impaired hepatic LDL-receptor in Cholesterol Medicines (E78.1: clearance); Cross-referenced with NIH MeSH (Nicotinic Acids, Hydroxymethylglutaryl-CoA Reductase Inhibitors), specialists in Cholesterol, Triglycerides & Lipids monitor LDL Cholesterol [Cholesterol Medicines E78.1] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • You have already had a heart attack or stroke , or you have peripheral arterial disease
- • Your LDL (bad) cholesterol level is 190 mg/dL or higher
- • Presentation of Cholesterol Medicines (E78.1): silent elevation of in Cholesterol Medicines (E78.1: LDL-C, ApoB100, or)
- • Secondary Cholesterol Medicines clinical sign: elevated triglyceride-to-HDL ratio [Cholesterol Medicines E78.1]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cholesterol Medicines Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E78.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Cholesterol Medicines E78.1] | < 70 mg/dL (< 55 mg/dL high risk) (E78.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: LDL Cholesterol [Cholesterol Medicines E78.1] | < 85 mg/dL (E78.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Triglycerides [Cholesterol Medicines E78.1] | < 100 mg/dL (E78.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cholesterol Medicines
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Brukinsa (Zanubrutinib) Brukinsa • RxCUI RXN-B72579122 | Kinase Inhibitor | 83% | $0.9900 | $ 79.78 /mo |
| Avapritinib Ayvakit • RxCUI RXN-72064110-2593 | Kinase Inhibitor | 88% | $3.3100 | $ 142.56 /mo |
| Zanubrutinib Brukinsa • RxCUI RXN-72579122-2253 | Kinase Inhibitor | 80% | $3.2000 | $ 138.10 /mo |
| Ayvakit (Avapritinib) Ayvakit • RxCUI RXN-B72064110 | Kinase Inhibitor | 88% | $2.5100 | $ 189.22 /mo |
| Tislelizumab-Jsgr Tevimbra • RxCUI RXN-72579121-2252 | Programmed Death Receptor-1 Blocking Antibody | 83% | $1.3300 | $ 62.37 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cholesterol Medicines)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Inclisiran for the Treatment of high: What a 3,660-Participant Study Found In conclusions, in patients with high cholesterol, inclisiran decreased LDL level by 51% without significant adverse effects. The American journal of cardiology • 2020-11-01 • Meta-Analysis | N = 3,660 | 99/100 | PMID 32892993 ↗ |
| New Insights on Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes and high: What a 1,229-Participant Study Found Ezetimibe/simvastatin provided additional lipid-modifying benefits over atorvastatin single-drug treatment at the recommended usual starting and next highest doses in patients with type 2 diabetes. Mayo Clinic proceedings • 2006-12-15 • Randomized Controlled Trial | N = 1,229 | 96/100 | PMID 17165637 ↗ |
| New Insights on Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus: What a 2,959-Participant Study Found Ezetimibe/simvastatin was more effective than rosuvastatin in LDL-C lowering, and provided greater or comparable improvements in other lipid measures and hsCRP at the approved usual starting, next highest, and maximum doses in... Current medical research and opinion • 2006-10-15 • Randomized Controlled Trial | N = 2,959 | 96/100 | PMID 17022864 ↗ |
| New Insights on Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin: What a 2,067-Participant Study Found Evolocumab reduced LDL-C levels by 66% (95% CI, 58% to 73%) to 75% (95% CI, 65% to 84%) (every 2 weeks) and by 63% (95% CI, 54% to 71%) to 75% (95% CI, 67% to 83%) (monthly) vs placebo at the mean of weeks 10 and 12 in the... JAMA • 2014-05-14 • Phase III Randomized Trial | N = 2,067 | 96/100 | PMID 24825642 ↗ |
| New Insights on Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering: What a 2,321-Participant Study Found Factors including statin absence, female sex, diabetes history, ezetimibe use, and a higher high-sensitivity C-reactive protein level may be useful to identify patients who may have a greater LDL-C reduction with BA. Journal of the American Heart Association • 2022-08-02 • Phase III Randomized Trial | N = 2,321 | 96/100 | PMID 35916348 ↗ |
Cholesterol Medicines Patient Community & “People Like Me” Threads
Filter Cholesterol Medicines community threads and patient logs by age, biological sex, dosage, and treatment duration.